JNJ03.BK Johnson & Johnson
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 1.19%
- Fundamental score
- -
Is JNJ03.BK undervalued?
Graham numberThe Graham number of Johnson & Johnson cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Johnson & Johnson fundamental analysis
No fundamental analysis for Johnson & Johnson yet.
Johnson & Johnson stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers,…
Full company profileFinancial statements of Johnson & Johnson are not available yet.
Johnson & Johnson dividends
Johnson & Johnson has not paid dividends in the last 3 fiscal years.
Who owns Johnson & Johnson
Ownership data of Johnson & Johnson is not available yet.
Johnson & Johnson company profile
- Company name
- Johnson & Johnson
- Ticker
- JNJ03.BK
- Exchange
- Thailand Exchange
- Sector
- -
- Industry
- -
- Employees
- 138,200
- Fiscal year end
- December
- Address
- One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933
- Phone
- 732 524 0400
- Website
- jnj.com
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Johnson & Johnson management
10- Mr. Joaquin DuatoCEO & Chairman · born 1963
- Mr. Joseph James Wolk CPAExecutive VP & CFO · born 1967
- Dr. John C. Reed M.D., Ph.D.Executive Vice President of Innovative Medicine and R&D · born 1958
- Mr. Timothy SchmidExecutive VP & Worldwide Chairman of MedTech · born 1970
- Mr. Robert J. Decker Jr.Controller & Chief Accounting Officer · born 1973
- Mr. James SwansonExecutive VP & Chief Information Officer · born 1966
- Mr. Ryan KoorsVice President of Investor Relations
- Mr. Dirk BrinckmanChief Compliance Officer
- Ms. Elizabeth Forminard J.D.Executive VP & Chief Legal Officer · born 1971
- Ms. Kristen Blair MulhollandExecutive VP & Chief Human Resources Officer · born 1967